Deployment and Smokeless Tobacco Use Among Active Duty Service Members in the US Military
Deployment and Smokeless Tobacco Use Among Active Duty Service Members in the US Military
复制标题
DOI:
10.1093/milmed/usy186
复制
发表时间:
2019-03-01
影响因子:
1.2
通讯作者:
Lee, Sukhyung
中科院分区:
文献类型:
--
作者:
Lin, Jie;Zhu, Kangmin;Lee, Sukhyung
Introduction: The prevalence of smokeless tobacco use among U.S. active duty service members has been much higher than in the U.S. general population. The association between deployment and smokeless tobacco use has not been well studied. We investigated the association between deployment and smokeless tobacco use among U.S. active duty service members. We also evaluated the modification effects from other factors related to smokeless tobacco use on the deployment-smokeless tobacco use association. Materials and Methods: Eligible active duty service members stationed at two military installations (Fort Bragg, NC, USA and Lackland Air Force Base, TX, USA) were recruited from July 2015 to May 2016. Each participant completed a self-administered questionnaire. Multivariable logistic regression was used to assess the association between deployment and smokeless tobacco use and estimated odds ratio (OR) and 95% confidence interval (CI). Stratified analysis was performed to evaluate modification effects from other commonly known factors related to smokeless tobacco use in military, specifically, cigarette smoking status, use among family members (family history of use), perception of harm, and use among military peers. Results: Out of 2,465 study participants who completed the questionnaire, 548 were smokeless tobacco users. Service members who had been deployed to a combat zone had 1.39 fold (95% CI = 1.03-1.87) increased odds of using smokeless tobacco than those who never deployed to a combat zone. The odds of smokeless tobacco use among those who had been deployed once, twice, three times and four or more times to a combat zone were 1.27 (95% CI = 0.91-1.78), 1.30 (95% CI = 0.85-1.99), 2.49 (95% CI = 1.45-4.28), and 2.88 (95% CI = 1.71-4.86), respectively, with a significant dose-response trend (p for trend